glp-1 news today october 2025 trends 2025: real-world data, patient outcomes & future therapies In 2026, it feels like

Affiliated providers are out-of-network with all health insurance plans, including Medicare and Medicaid

Beide Wege haben also eine unterschiedliche Logik

A Medicare GLP-1 Bridge program covering Wegovy and Zepbound at a $50/month Part D copay is reported as beginning July 2026

In Phase II trials, MariTide demonstrated up to approximately 20% average weight loss at 52 weeks in people living with obesity or overweight, without evidence of a plateau, suggesting even greater results with longer treatment

This suggests that even modest lipid improvements combined with weight loss, reduced inflammation, and improved glucose control may contribute to overall cardiovascular risk reduction in some patients